Medidata Signs Multi-Year Agreement with Bristol Myers Squibb to Extend Relationship and Continue Company’s Use of Platform
Collaboration underscores Bristol Myers Squibb’s commitment to unleashing the power of digital technologies to advance its mission to discover, develop, and deliver Innovative medicines that help patients prevail over serious diseases
New York – Jan. 7, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers Squibb to help enhance the company’s clinical research processes, advance patient outcomes, and foster personalized healthcare.
Bristol Myers Squibb will continue to leverage the Medidata Platform, and is working with Medidata to evaluate additional components of their suite of products including AI and advanced analytics, innovative data management solutions, and the newly launched Medidata Clinical Data Studio to help manage, monitor, and analyze its clinical trials. This strategic extension will enable Bristol Myers Squibb to deepen engagement with trial sites and patients while streamlining processes and expediting the delivery of life-changing therapies to those in need.
“We are honored to continue working with BMS in their efforts to leverage the Medidata Platform and unify more of their clinical trial ecosystem.” said Janet Butler, executive vice president, head of global sales, Medidata. “As the use of AI evolves quickly in our industry, it’s exciting to see leaders like BMS adopt practical and impactful technology beyond EDC to speed research and add efficiency for sites.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 350,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
Contact:
Medidata PR
Analyst Relations
